Author

Timothy M. Cunniff

Observed names: T. Cunniff, Timothy Cunniff

Observed institution: Chicago Public Library

OpenAlex ID: A5015590542

Ecopipam for Tourette Syndrome: A Randomized Trial

2023 · Donald L. Gilbert, Jordan S. Dubow, et al. · PEDIATRICS · 39

Safety and Effect of 12‐Month Ecopipam Treatment in Pediatric Patients with Tourette Syndrome

2025 · Donald L. Gilbert, David J.B. Kim, et al. · Movement Disorders Clinical Practice · 10

PDF

Efficacy and Safety of Ecopipam for Tourette Syndrome

2026 · Donald L. Gilbert, Sarah D. Atkinson, et al. · JAMA Neurology · 8

Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy

2025 · Joseph F. McGuire, George B. Karkanias, et al. · Journal of Child and Adolescent Psychopharmacology · 7

PDF

Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators

2026 · Kinga K. Tomczak, Jason P. Swindle, et al. · Frontiers in Psychiatry · 1

PDF

Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results from the Phase IIb (D1AMOND) Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome (S30.009)

2024 · Donald Gilbert, George Karkanias, et al. · Neurology · 1

Design of a Phase 3 Maintenance-of-Effect Trial of Ecopipam in Tourette Syndrome (P12-11.011)

2023 · Timothy Cunniff, Donald Gilbert, et al. · Neurology · 1

Increasing Ecopipam Exposure Improves Yale Global Tic Severity Scale-Total Tic Scores (YGTSS-TTS) in Children and Adolescents with Tourette Syndrome (TS): Results from a Population Pharmacokinetic (popPK) Model-Based Simulation Using D1AMOND Trial Data (P5-9.007)

2023 · Soha Freidy, Teodora Dumitrescu, et al. · Neurology · 1

Potential mechanisms for prolonged loss of ambulation with deflazacort in Duchenne muscular dystrophy – Tolerability profile and effects on growth

2016 · J. Meyer, T. Cunniff, et al. · Neuromuscular Disorders · 1

Effect of deflazacort and prednisone on muscle enzymes in the treatment of Duchenne muscular dystrophy

2016 · J. Dubow, T. Cunniff, et al. · Neuromuscular Disorders · 1

Effect of Deflazacort and Prednisone versus Placebo on Muscle Strength in Boys with Duchenne Muscular Dystrophy Who Have Lost Ambulation: Results from the Deflazacort Clinical Trial Program (S28.006)

2016 · Timothy Cunniff, Stephen Wanaski, et al. · Neurology · 1

Effect of Deflazacort and Prednisone Versus Placebo on Pulmonary Function in Boys with Duchenne Muscular Dystrophy Who Have Lost Ambulation (I4.009)

2016 · Jordan Dubow, Timothy Cunniff, et al. · Neurology · 1

1.70 The Safety and Effect of Ecopipam During the First 8 Weeks of Tourette’s Disorder Treatment: A Post-Hoc Analysis

2026 · Kinga K. Tomczak, Tamar C. Katz, et al. · Journal of the American Academy of Child & Adolescent Psychiatry

1.71 Long-Term Safety and Effect of Ecopipam, a Selective Dopamine D1 Receptor Antagonist, in Children, Adolescents, and Adults With Tourette's Disorder

2026 · Donald L. Gilbert, Kevin J. Black, et al. · Journal of the American Academy of Child & Adolescent Psychiatry

1.74 The Presence of Common Psychiatric Diagnoses Did Not Impact the Efficacy or Safety of Ecopipam in Individuals With Tourette’s Disorder

2026 · Joseph F. McGuire, John A. Flatt, et al. · Journal of the American Academy of Child & Adolescent Psychiatry

Targeting Dopamine Pathways for the Treatment of Tourette Syndrome

2026 · George B. Karkanias, John A. Flatt, et al. · Journal of Child Neurology

Exposure-response (ER) and Clinical Trial Simulations for Efficacy of Ecopipam in Adults and Pediatrics with Tourette’s Syndrome (TS) (P2-16.001)

2026 · Stephen Wanaski, Soha Freidy, et al. · Neurology

Real-world Adverse Event Profile and Comorbidity Index in Children and Adolescents with Tourette Syndrome (TS) Treated with Dopamine D2 Receptor Antagonists (P11-8.011)

2026 · David Isaacs, Jason Swindle, et al. · Neurology

Receptor Selectivity Profile and Clinical Significance of Ecopipam and Relevant Metabolites: A Potential New Treatment for Tourette Syndrome (TS) (P2-16.002)

2026 · Stephen Wanaski, Virginia Schmith, et al. · Neurology

Efficacy and Safety of Ecopipam for Tourette Syndrome: Results from a Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Trial (PL5.004)

2026 · Kinga Tomczak, Sarah Atkinson, et al. · Neurology

Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette Syndrome

2026 · Donald L. Gilbert, David J. B. Kim, et al. · Therapeutic Advances in Neurological Disorders

6.74 Efficacy of Ecopipam on Motor and Phonic Tics in Tourette’s Disorder: Data From a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

2025 · Donald L. Gilbert, Sarah D. Atkinson, et al. · Journal of the American Academy of Child & Adolescent Psychiatry

Changes in Metabolic Parameters and Determination of Minimal Clinically Important Difference in YGTSS-TTS Using Data From the Randomized Phase 2b and Open-Label Extension Studies of Ecopipam For Tourette Syndrome (P11-6.002)

2025 · Joesph F. McGuire, George B. Karkanias, et al. · Neurology

The Effect of Ecopipam and its Metabolites on Cardiac Repolarization, QTcF (P10-5.014)

2025 · Stephen Wanaski, Hongqi Xue, et al. · Neurology

High Rates of Discontinuation of D2 Receptor Antagonists as First-Line Treatment of Tourette Syndrome in Children: A Retrospective Database Analysis (P11-6.001)

2025 · Kinga Tomczak, Jason Swindle, et al. · Neurology

Works count: 42

Citation count: 72

H-index: 4

I10-index: 2